New World Development Co. Ltd. (HKEX:0017) stated no agreement has been reached with any potential investors, refuting recent media speculation about imminent funding or partnership deals as of January 29, 2026.

The Hong Kong-based property developer emphasized that all material transactions will be disclosed via official channels in compliance with listing rules. The statement follows unconfirmed reports suggesting negotiations with strategic investors to bolster its balance sheet amid a prolonged real estate downturn.

As of Q2 2025, the company reported HK$386 billion in total assets and net debt of HK$102 billion. Its shares closed down 2.4% on January 29, 2026, underperforming the Hang Seng Property Index, which fell 1.1%.

Nokia Oyj (NYSE: NOK) restated its 2024 and 2025 segment financials on January 29, 2026, to align with a revised internal reporting structure, impacting comparability of historical performance metrics.

The recast affects revenue and operating profit allocations across Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The company emphasized the changes are organizational, not accounting-related, and do not alter consolidated financial statements or prior guidance.

Investors should review updated segment disclosures in Nokia’s Q4 2025 earnings release for accurate period-over-period analysis. Management stated the restructuring aims to improve strategic focus and operational transparency ahead of 2026 planning cycles.

European equities erased early gains to close mixed on January 29, 2026, as investor sentiment wavered on renewed uncertainty over ECB rate policy and weak corporate earnings in the industrial sector.

The Stoxx Europe 600 ended flat at 512.34, with utilities and healthcare stocks advancing while autos and banks declined. Germany’s DAX fell 0.4%, France’s CAC 40 rose 0.2%, and the UK’s FTSE 100 gained 0.3%. Analysts cited comments from ECB officials hinting at prolonged higher rates as a key headwind. “Markets are struggling to price in a clear path for monetary easing,” said Lena Vogt, chief strategist at Commerzbank Research.

President Donald Trump announced on January 29, 2026, that Eli Lilly (LLY) plans to construct six new U.S. manufacturing facilities, citing a conversation with the company’s CEO. Trump called the executive “a star” during a White House cabinet meeting.

Eli Lilly previously committed to investing at least $27 billion to build four U.S. plants—already announcing locations in Alabama, Virginia, and Texas—to expand drug production and strengthen domestic supply chains. The company has not confirmed the additional two facilities mentioned by Trump and did not immediately respond to requests for comment.

Tesla CEO Elon Musk declared on the Q4 2025 earnings call (Jan 28, 2026) that the company is pivoting from automotive manufacturing to an “embodied AI” future centered on autonomy, robotaxis, and humanoid robots. The Model S and Model X will be phased out as Tesla allocates resources to six new production lines for Cybercab robotaxis and Optimus robots.

Analysts at Canaccord Genuity, Piper Sandler, and Barclays frame this as a strategic inflection point. Tesla now counts 1.1 million Full Self-Driving (FSD) subscribers — up 38% YoY — and plans to expand its robotaxi fleet from 500 vehicles in Austin/SF to surpass Waymo’s 2,000 by April 2026. The Cybertruck will transition to autonomous cargo delivery. Optimus Gen 3 launches this quarter, targeting 1M units/year by end-2026, potentially generating $25B annually at $50K ASP. Wedbush projects a $2T–$3T market cap by end-2026.

Health care affordability has become Americans’ leading financial concern as premiums surge following Congress’s 2025 failure to renew ACA subsidies, according to a KFF poll conducted January 13–20, 2026.

Two-thirds of U.S. adults report being very or somewhat worried about medical costs — surpassing concerns over food, housing, or utilities. One-third say they are “very worried.” Over half report higher health expenses in the past year. KFF analyst Shannon Schumacher notes rising out-of-pocket and insurance costs are pushing health care to “top of mind” amid broader inflation pressures.

While 76% of Americans say incomes aren’t keeping pace with inflation, 67% disapprove of letting ACA subsidies expire. Some consumers now plan to drop coverage or switch to skimpier plans. Other top worries: food (24% very worried), housing (23%), utilities (22%), and transportation (17%).

Gold fell to $5,300/oz on January 29, 2026, retreating from a $5,600 intraday peak, while silver pared gains after hitting $120/oz. The pullback coincided with a Nasdaq drop of up to 2%, triggered by Microsoft’s earnings miss and rising capex concerns.

The dollar rebounded from 2022 lows, halting the precious metals’ parabolic rally. Saxo Bank’s Ole Hansen warned the surge is entering a “dangerous phase,” citing self-feeding volatility and thinning liquidity. Gold is up 20% YTD; silver, 42%.

Goldman Sachs maintains a $5,400 year-end target, citing private investor inflows. JPMorgan noted silver has overshot forecasts but cautioned against calling a top amid momentum-driven trading. Fed’s dovish hold and Powell’s comments had earlier fueled dollar weakness.

Aprea Therapeutics (APRE) announced on January 29, 2026, that its drug candidate APR-1051 demonstrated clinical activity in endometrial cancer patients during early trials, prompting the company to secure $5.6 million in a private placement to fund further development.

The financing, led by existing institutional investors, priced at-market and includes warrants. Proceeds will support ongoing Phase 1/2 studies evaluating APR-1051 as a monotherapy and in combination regimens. The compound targets mutant p53 reactivation, a mechanism implicated in multiple solid tumors.

Aprea reported preliminary data showing tumor reduction in heavily pretreated patients. The company plans to present updated results at a medical conference in Q2 2026. APRE shares closed at $1.82 on Nasdaq prior to the announcement.

U.S. factory orders jumped 1.8% in November 2025, far exceeding the 0.8% consensus forecast, signaling resilient industrial demand despite elevated interest rates.

The Commerce Department reported durable goods orders rose 2.2%, led by transportation equipment, while core capital goods orders — a proxy for business investment — climbed 0.9%. October’s figure was revised slightly higher to -0.2%. The rebound suggests manufacturing may be stabilizing after months of contraction, offering policymakers cautious optimism ahead of the Fed’s February meeting.

Shipments and unfilled orders also rose, indicating sustained pipeline pressure. Inventories edged up 0.3%, suggesting firms remain confident in near-term demand.

U.S. wholesale inventories increased 0.2% in November 2025, following a revised 0.1% gain in October, according to the U.S. Census Bureau. The modest buildup reflects cautious restocking amid rising sales, which jumped 0.6% month-over-month.

Inventories of durable goods edged up 0.3%, led by machinery and computer equipment, while nondurable goods inventories were flat. The inventory-to-sales ratio fell to 1.27 from 1.28 in October, indicating faster turnover and improved supply chain efficiency.

The data suggests businesses are aligning stockpiles with demand rather than overbuilding ahead of uncertain economic conditions. Analysts note the trend supports expectations for stable GDP growth in Q4 2025, though persistent inflation risks remain.

YD Bio (NASDAQ: YDBO) signed a non-binding letter of intent on January 29, 2026, to acquire Safe Save Medical, aiming to expand its immunocell therapy capabilities and market leadership.

The acquisition targets Safe Save’s proprietary T-cell expansion and tumor-targeting platforms, which complement YD Bio’s existing pipeline in solid tumor treatments. Financial terms were not disclosed, pending due diligence and definitive agreement. YD Bio stated the deal would accelerate clinical development timelines and broaden its addressable patient population.

Safe Save Medical, privately held, has completed Phase I trials for two autologous cell therapies. YD Bio expects the transaction to close by Q3 2026, subject to regulatory approvals. Shares of YDBO rose 4.7% in after-hours trading following the announcement.

Dover Corporation (NYSE: DOV) will host its Q4 2025 earnings conference call at 12:00 PM ET on January 30, 2026. Management will discuss financial results and operational performance for the quarter ended December 31, 2025.

The call will be accessible via webcast on the company’s investor relations website. A replay will be available for 30 days following the event. Analysts and institutional investors are expected to assess guidance for FY2026 and margin trends across Dover’s engineered products, fluid solutions, and refrigeration segments.

No preliminary financial figures were disclosed in the announcement. The company last reported Q3 2025 revenue of $2.1B and adjusted EPS of $2.48.

Microsoft Corp. (MSFT) shares plunged on January 29, 2026, triggering a broad selloff across U.S. equity markets as investors reacted to weaker-than-expected cloud revenue guidance.

The tech giant fell over 8% in after-hours trading following its quarterly earnings release, which showed Azure growth slowing to 24% year-over-year — below consensus estimates of 27%. CEO Satya Nadella cited enterprise spending caution and elongated deal cycles. The Nasdaq Composite dropped 2.1%, while the S&P 500 shed 1.4% during regular session close.

Analysts at J.P. Morgan downgraded MSFT to “Neutral,” citing margin pressure from AI infrastructure costs. Competitors Amazon (AMZN) and Google (GOOGL) also declined 3.2% and 2.8%, respectively, amid sector-wide contagion fears.

Alpha Tau Medical (NASDAQ: DRTS) highlights five ongoing U.S. clinical trials with multiple data readouts expected in 2026, though shares fell 4.2% on January 29, 2026, amid investor caution over trial timelines and commercialization risks.

The trials target recurrent head and neck cancers, pancreatic cancer, and soft tissue sarcomas using its Alpha DaRT radiotherapy technology. Management expects interim safety data from three trials by Q2 2026 and preliminary efficacy results from two others by Q3 2026.

Analysts note the company’s cash runway extends into early 2027, but warn that delays or underwhelming data could pressure the stock further. Alpha Tau has no approved products and generated $0 in revenue in 2025.

IGO Limited (ASX: IGO) reported a quarter-over-quarter decline in Q2 sales revenue as of January 29, 2026, driven by softer nickel prices and reduced production volumes at its Western Australia operations.

Revenue fell 12% sequentially to $487 million, with nickel sales down 18% due to planned maintenance at the Nova and Forrestania sites. CEO Peter Bradford noted “market headwinds and operational downtime” pressured near-term results but affirmed full-year guidance remains unchanged.

The company holds a 49% stake in the Greenbushes lithium mine and is advancing its integrated battery materials strategy. Shares traded down 3.2% in Sydney following the release.

The Toronto Stock Exchange (TSX) reversed early gains and closed lower on January 29, 2026, dragged down by a tech sector selloff after Microsoft issued a weaker-than-expected revenue forecast.

Microsoft (MSFT) projected Q2 cloud growth below analyst estimates, triggering a 4.2% drop in its shares after hours and spilling over into Canadian tech names like Shopify (SHOP), which fell 5.1%. The S&P/TSX Composite Index ended down 1.3% at 21,450. Broader market sentiment soured despite strong morning momentum fueled by energy and financials.

Investors are now reassessing tech valuations amid slowing enterprise spending. “Microsoft’s guidance is a red flag for global IT demand,” said Lena Cho, chief strategist at Veritas Capital. U.S. Nasdaq futures also dipped 1.8% in late trading.

Oakworth Capital Inc. (NASDAQ: OKWR) reported stronger fourth-quarter net income on January 29, 2026, driven by improved loan yields and lower credit loss provisions.

Net income rose 18% year-over-year to $4.7 million, or $0.31 per diluted share, up from $0.26 in Q4 2025. Total revenue climbed 9% to $12.1 million, supported by a 22-basis-point expansion in net interest margin. Non-performing assets fell to 0.8% of total assets, down from 1.3% a year earlier. CEO James A. Freeman stated, “Our disciplined underwriting and funding cost management delivered resilient performance amid volatile markets.”

The company declared a quarterly dividend of $0.08 per share, payable February 15, 2026, to shareholders of record as of February 5.

The U.S. trade deficit ballooned 94.6% month-over-month in November 2025 to $56.8 billion, the largest single-month increase since 1992, as imports surged and exports fell sharply, reflecting volatility from Trump-era tariff rhetoric.

Imports rose 5% to $348.9 billion, led by record capital goods (+$7.4B, driven by AI-related semiconductors) and consumer goods (+$9.2B, mainly pharmaceuticals). Exports dropped 3.6% to $292.1 billion, weighed down by falling industrial supplies and pharmaceutical shipments. The inflation-adjusted goods deficit hit $87.1 billion — a four-month high — likely trimming Q4 GDP growth expectations. The Atlanta Fed’s GDPNow model previously projected net exports adding 1.88 percentage points to Q4 growth; economists now expect downward revisions. Trade gaps with China and Canada widened, while Mexico’s narrowed slightly.

Comcast pivots to sports-driven growth after losing the Warner Bros. bid, banking on Winter Olympics, Super Bowl, NBA, and World Cup broadcasts via NBCUniversal in 2026. Peacock streaming surged to 44M subscribers with 23% revenue growth to $1.6B, but Q4 losses widened to $552M due to NBA rights and exclusive NFL game costs.

Executives say Peacock cut annual losses by $700M vs. 2024’s $1.1B deficit, though profitability remains distant. Comcast spun off profitable cable networks into “Versant” as it shifts from legacy TV to integrated media anchored by sports, studios, and theme parks. Q4 revenue rose slightly to $32.3B; adjusted EPS fell 12% to 84 cents. Theme parks revenue jumped 22% to $2.9B, while studio revenue dropped 7.4%. Shares rose 4.3% to $29.63.

Initial U.S. jobless claims fell by 1,000 to 209,000 for the week ended January 24, 2026, signaling sustained low layoffs despite hiring caution. The prior week was revised up to 210,000. Continuing claims dropped 38,000 to 1.827 million, though seasonal distortions and benefit exhaustion may skew figures.

The trade deficit ballooned 94.6% to $56.8 billion in November 2025 — the largest jump since March 1992 — driven by record capital goods imports tied to AI investment. Imports surged 5.0% to $348.9B; exports fell 3.6% to $292.1B. Atlanta Fed slashed Q4 GDP growth to 4.2% from 5.4%; Goldman cut to 2.0% from 2.4%. Markets dipped as uncertainty over tariffs, labor supply, and a potential Jan 30 government shutdown looms.